Michael Salako

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom.

Babraham Bioscience Technologies Ltd. provides business research and consulting services. It also offers financial and administrative services to start-up biotech companies. The company was founded in 1996 and is located in Cambridge, UK

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

LGV Capital (LGV) is a private equity subsidiary of Legal & General Group Plc (LSE: LGEN), founded in 1986. The firm is headquartered in London.

Oxford Capital Partners LLP (Oxford Capital Partners) is a venture capital subsidiary of Oxford Capital Partners Holdings Ltd founded in 1999 by Tedd Mott and David Edward Christian Mott. The firm is headquartered in Oxford, United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

MRC Laboratory of Molecular Biology provides biological research and development services. it also offers methods for determining the three-dimensional structures of proteins and other macromolecules, the sequencing of DNA and the development of monoclonal antibodies. The company was founded by Max Ferdinand Perutz in 1962 and is headquartered in Cambridge, the United Kingdom.

Buckman Laboratories SARL wholesales chemicals to the paint industry. The firm markets its products under the brand names such as BUCKMAN, BUFLOC, BULAB, BUSAN, BUSPERSE, and BUTROL. The company was founded on December 21, 2007 and is headquartered in Wasquehal, France.

Stevenage Bioscience Catalyst offers access to equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies. The company is headquartered in Stevenage, the United Kingdom.

ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom.

Ieso Digital Health Ltd. provides Internet enabled mental health services to health providers, private individuals and businesses. The firm engages in delivering cognitive behavioral therapy. It offers anxiety, bereavement, child and family, depression, drug and alcohol misuse, eating disorder, managing anger, managing pain, obsessive compulsive disorder, panic, phobia, post traumatic stress, relationship, sexual difficulty, sports psychology, stress management, and terminal illness therapy services. The company was founded by Barnaby Perks, Sue Wright and Nadine Field in 2000 and is headquartered in Cambridge, the United Kingdom.

Axol Bioscience Ltd. is a biotech company that develops and produces induced pluripotent stem cell-derived clinically relevant cells for use in biomedical research and discovery. Its products include human neural progenitor cells, young frozen human cerebral cortical neurons, plated human cerebral cortical neurons, Alzheimer's disease human neural progenitor cells, reagents, and lipid-based transfection reagents. The firm's products are used in the testing of new drug compounds, as well as in the development of therapies for various diseases, such as Alzheimer’s. The company was founded by Yichen Shi and Jonathan Simon Milne and is headquartered in Cambridge, the United Kingdom.

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom.

Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom.

Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Sense Biodetection Ltd. provides molecular diagnostics research services. It focuses on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology. The company was founded by Harry John Lamble and Ralph Lamble in 2014 and is headquartered in Abingdon, the United Kingdom.

Avocet 66 Ltd. is a British financial intermediary company founded in 2017.

Peregrine 66 Ltd. is a British investment services company founded in 2017. The private company is based in London, UK. The company provides investment services.

Suntail 66 Ltd. provides financial intermediary services. The private company is based in London, UK.

Proteorex Therapeutics, Inc. develops novel therapeutics. It is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. The firm’s drug discovery platform integrates a novel synthesis design strategy, machine learning, and patient-derived cell-based screening to unlock targets considered undruggable using existing approaches. The company was founded by Aman Iqbal, Kong T. Nguyen, Robert Batey and Michael Anstey and is headquartered in Toronto, Canada.

Polyprox Therapeutics Ltd. operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases. The company was founded by Laura S. Itzhaki in 2018 and is headquartered in Cambridge, the United Kingdom.

Apollo Therapeutics LLP is a British biopharmaceutical company that focuses on translating medical research into medicines. The company is based in Stevenage, UK. The company has a portfolio-model built around a centralized management team of experts in pharmaceutical R&D, manufacturing, commercial strategy, fundraising, and business development. The company's assets are housed in separate wholly-owned subsidiary companies, which incorporate best practices from big pharma and venture capital. The company has a scalable R&D platform for the discovery and development of new medicines, enabled by access to five of the world's leading universities and research institutes. The company was founded in 2015, and the CEO is Richard Mason.

Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation.

Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021.

Apollo Therapeutics Group Ltd. is an investment holding British company. The private company is based in Cambridge, UK. The company was founded in 2021. The CEO is Richard Mason.

Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom.